# Lifeward Ltd. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Lifeward Ltd.). ## Overview Lifeward Ltd. develops and commercializes mobility and rehabilitation technologies for people with spinal cord injury and other mobility-limiting conditions. Its portfolio centers on the ReWalk personal exoskeleton, AlterG anti-gravity systems, ReStore, and MyoCycle, with revenue also coming from warranties and repair services. ## Products & services • ReWalk Personal Exoskeleton and ReWalk 7 • AlterG Anti-Gravity systems • ReStore rehabilitation system • MyoCycle device • Extended warranties and repair services - **Exoskeleton mobility systems** (45%) — Wearable robotic devices used by individuals with spinal cord injury to stand and walk. - **Rehabilitation and anti-gravity systems** (35%) — Clinic-based systems such as AlterG and ReStore used for therapy, gait training, and recovery. - **Home and personal therapy devices** (10%) — Smaller devices such as MyoCycle sold to rehabilitation users and personal users. - **Services and support** (10%) — Extended warranties, repairs, and related post-sale support for installed products. - ReWalk Personal Exoskeleton and ReWalk 7 - AlterG Anti-Gravity systems - ReStore rehabilitation system - MyoCycle device - Extended warranties and repair services ## Customers Lifeward sells to a mix of end users and institutional buyers, with direct sales in the United States and distributor-led sales in many international markets. Core customers include clinics, rehabilitation centers, third-party payors, professional and college sports teams, veterans programs, and self-pay individuals, especially in the SCI community. - **Rehabilitation clinics and centers** (primary) — Buy AlterG, ReStore, and related systems for therapy, gait training, and patient rehabilitation. - **SCI patients and self-pay individuals** (primary) — Purchase ReWalk personal exoskeletons and MyoCycle devices for mobility and home use. - **Third-party payors and government programs** (primary) — Do not buy directly, but determine reimbursement access that drives adoption of ReWalk systems. - **Distributors and channel partners** (secondary) — Buy or resell products in non-direct markets and provide local market access and service coverage. - **Sports teams** (secondary) — Use AlterG systems for training, recovery, and performance applications. - Clinics and rehabilitation centers buying systems for therapy and gait training - SCI patients and self-pay individuals purchasing personal mobility devices - Third-party payors and government programs influencing reimbursement access - Professional and college sports teams using AlterG for training and recovery - Distributors abroad that sell into local rehab and medical channels ## Geography Lifeward’s principal markets are the United States and Europe, with smaller sales in Asia, the Middle East, and South America. The company has primary offices in Yokneam, Israel; Marlborough, Massachusetts; and Berlin, Germany, and it previously operated offices in Fremont, California and Queens, New York, which were closed at the end of 2024. - **United States** (60%) — Principal market and direct-sales focus - **Europe** (30%) — Major market with direct and distributor-led sales - **Rest of world** (10%) — Smaller sales in Canada, Asia, Middle East, and South America - United States is the main direct-sales market and reimbursement focus - Europe is a major market, with direct and distributor sales in Germany - Canada is served through a mix of direct sales and distributors - Smaller sales come from Asia, the Middle East, and South America - Operations span Israel, the U.S., and Germany, affecting supply and support ## Strategy Lifeward is focused on expanding reimbursement coverage for ReWalk, especially through commercial and government payors, while increasing placements of AlterG and MyoCycle. Management is also trying to lower product costs, improve commercial efficiency, and broaden the company’s clinical and commercial footprint. - **Reimbursement expansion for ReWalk** (short-term) — Coverage determines adoption for a high-cost device and directly affects sales conversion. - **Commercialization of ReWalk 7 in Europe** (short-term) — CE mark approval enables broader European sales and diversifies the revenue base. - **Cost reduction and operational efficiency** (medium-term) — Lower material costs and leaner operations are important given losses and limited liquidity. - **Broaden product portfolio penetration** (medium-term) — Growth depends on selling more AlterG and MyoCycle units across rehab and personal channels. - Expand reimbursement coverage for ReWalk through commercial and government payors - Grow AlterG penetration in rehabilitation clinics in the U.S. and abroad - Increase MyoCycle placements with clinics and personal users - Reduce material costs through product design enhancements - Optimize commercial operations and lower cash burn ## Risks Lifeward faces execution risk from its manufacturing transition, reimbursement dependence, and limited liquidity. The business also has exposure to tariffs and foreign sourcing, while its Nasdaq listing status and going-concern profile add financing and market-risk pressure. - **Manufacturing transition to in-house production** [high] — The company moved ReWalk manufacturing away from Sanmina and must build internal capabilities and supplier relationships. - **Reimbursement and coverage uncertainty** [high] — Demand for exoskeletons depends heavily on third-party payor support, which is not uniform in the U.S. - **Tariffs and trade barriers** [medium] — The company relies on foreign manufacturers and parts suppliers, including in China, Taiwan, and Israel. - **Nasdaq Capital Market compliance** [medium] — Failure to satisfy listing requirements could threaten continued listing and liquidity in the stock. - **Going-concern and financing risk** [critical] — Cash resources are limited and the company expects further losses, requiring additional financing. - Manufacturing transition could disrupt supply, quality, and delivery timing - Reimbursement coverage is uneven and can limit ReWalk adoption - Tariffs on China, Taiwan, and Israel may raise input costs and hurt margins - Nasdaq listing compliance risk could affect market access and investor confidence - Low cash balance and going-concern uncertainty increase financing risk ## Accounting Revenue is driven by product sales plus warranties and repair services, so timing of shipment, acceptance, and service recognition can affect quarterly results. Investors should also watch estimates tied to intangible assets, deferred taxes, and any impairment or valuation issues arising from acquisitions and restructuring, especially given the company’s losses and limited liquidity. - **Revenue recognition for devices, warranties, and repairs** — Can shift reported revenue and gross margin between periods - **Intangible asset amortization** — Impacts sales and marketing or operating expense trends - **Going-concern assessment** — Affects disclosure, financing assumptions, and investor risk assessment - **Deferred tax and subsidiary timing differences** — Can create volatility in reported tax expense - Product sales and service revenue timing can shift quarter-to-quarter - Warranty and repair obligations affect deferred revenue and service margins - Acquisition-related intangible amortization affects operating expenses - Deferred tax adjustments and subsidiary timing differences affect tax expense - Going-concern disclosures reflect liquidity assumptions and financing estimates --- *Last updated: 2026-04-28T20:22:55.404892+00:00*